SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Alzamend Neuro’s Phase 1/2A lithium neuroimaging data accepted for poster

Alzamend Neuro’s Phase 1/2A lithium neuroimaging data has been accepted for poster presentation at Neuroscience 2026 in Washington, DC, per Newsdesk.

ALZN

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.